Business
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate
About this update from Allogene Therapeutics, Inc.
[{"type":"text","content":"Report Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate Governance\nSOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today published its 2022 annual ESG report. The report provides an update on the Company’s robust efforts to retain talent, protect the environment, practice good corporate governance and most importantly, increase patient access to potentially life-saving products. “Last year, we took great pride in being one of the first companies of our size and in our industry to publish an ESG report as we look to make a difference for patients while being good corporate citizens,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene. “With our second report, we continue to embrace being the face of change as we have initiated the industry’s first potentially pivotal Phase 2 allogeneic CAR T trial and are the first company to demonstrate proof-of-concept for an AlloCAR T product in multiple diseases, including the potential for an AlloCAR T in the treatment of solid tumors.” The full ESG report is available on the Culture page and the Investor Relations section of the Company’s website. Highlights of the ESG report describe Allogene’s commitment to: Improving Access to CAR T Therapy: Because of its off-the-shelf nature, allogeneic CAR T addresses the limitations of autologous CAR T therapies and other modalities and has the potential to treat dramatically more patients, across more cancer types and at earlier stages, faster and with greater convenience. In 2022, Allogene launched the industry’s first potentially pivotal Phase 2 allogeneic CAR T trial, treating patients with large B cell lymphoma with ALLO-501A, the Company’s lead anti-CD19 AlloCAR T product.Creating a Diverse and Inclusive Workplace: The Company is proud of the diversity of its workforce and strives to enable opportunity for underrepresented minorities. Allogene continues to stand by its diversity, equity and inclusion (DEI) policy. Recruitment efforts are designed to attract candidates from underrepresented groups. Newly implemented interview practi...